Marc B. Garnick, MD, presented “Standard Treatments and Global Perspective” during the virtual 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in September 2021.
How to cite: Garnick, Marc B. Einstein, David. “Standard Treatments and Global Perspective.” September 2021. Accessed Dec 2024. https://grandroundsinurology.com/standard-treatments-and-global-perspective/
Standard Treatments and Global Perspective – Summary
Marc B. Garnick, MD, the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, summarizes recent developments in nomenclature, disease states, and standard treatments for advanced prostate cancer. Using material from a chapter he wrote for ASCO-SEP with David J. Einstein, MD, Assistant Professor of Medicine at Harvard Medical School, Dr. Garnick begins by considering the new language used to describe different states of advanced prostate cancer, including non-metastatic castrate-sensitive prostate cancer (nmCSPC), non-metastatic castrate-resistant prostate cancer (nmCRPC), metastatic castrate-sensitive prostate cancer (mCSPC), and oligometastatic prostate cancer. He then discusses new standards of care for these different states, highlighting recent research indicating the benefits of using darolutamide, enzalutamide, and apalutamide in the nmCRPC setting, and explaining how to appropriately layer and sequence therapies across disease states. He briefly looks at the role of next-generation sequencing in informing the potential benefit of PARP or PD-L1 inhibitors and touches on bone considerations in mCRPC. Dr. Garnick concludes with some comments on the global inequities of prostate cancer treatment, citing data on the significant disparity in mortality-to-incidence rate of prostate cancer in high-income countries compared to low- to middle-income countries.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and became seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. For more educational activities from this virtual event, visit our collection page.
ABOUT THE AUTHOR
Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, where he also directs the hospital’s role as a tertiary cancer center for 7 affiliated community cancer centers. He has dedicated his career to the development of new therapies for prostate cancer. He serves as the Editor-in-Chief for The Annual Report on Prostate Diseases, formerly Perspectives on Prostate Disease. He served as the initial academic co-principal investigator for the commonly used prostate cancer drug leuprolide (Lupron). In addition to his academic affiliations, Dr. Garnick founded the Hershey Family Foundation for Prostate Cancer Research at Beth Israel Deaconess Medical Center, serves as medical adviser to World Book Encyclopedia, and is an active advisory member of several FDA panels and advisory committees. He has served on the boards of trustees of the Perelman School of Medicine at the University of Pennsylvania and of Penn Medicine. Dr. Garnick is also a Trustee Emeritus of Bowdoin College in Brunswick, Maine.
